Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Objective
: Brain tumor-initiating cells are characterized by their features of self-renewal, multi-lineage differentiation, and tumorigenicity. We analyzed the gene expression of brain tumor-initiating cells to identify their novel cellular markers.
Methods:
We performed cDNA microarray,
in silico
expressed sequence tags (ESTs), RT-PCR, and q-PCR analyses.
Results
: We identified 10 genes that were more highly expressed in brain tumor-initiating cells than in neural stem cells. In addition, we identified 10 other genes that were more highly expressed in brain tumor-initiating cells than in
glioma
cell line cells from the cDNA microarray analysis. Using the EST database, we looked to see if the 20 genes were expressed more highly in gliomas, compared with normal adult brains. Among the 20 genes, five (
KLRC2
, HOXB2, KCNJ2, KLRC1, and COL20A1) were expressed more than twice in
glioma
samples, compared with normal adult brains, and, therefore, were referred for further evaluation. RT-PCR was conducted using cDNA samples obtained from neural stem cells, normal brain tissue, fetal brain tissue,
glioma
cell lines, and
glioma
tumor-initiating cell lines.
KLRC2
, a transmembrane activating receptor in natural killer cells, was expressed more highly in
glioma
-initiating cells than in neural stem cell lines or normal adult brain tissue. The q-PCR analysis revealed that expression of
KLRC2
was significantly higher in brain tumor-initiating cells compared to normal brain controls.
Conclusion
:
KLRC2
could be a novel cellular marker for brain tumor-initiating cells.
...
PMID:Identification of KLRC2 as a candidate marker for brain tumor-initiating cells. 3155 57